Sangamo Therapeutics Inc
NASDAQ:SGMO

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
NASDAQ:SGMO
Watchlist
Price: 1.88 USD -4.08% Market Closed
Market Cap: 391.5m USD
Have any thoughts about
Sangamo Therapeutics Inc?
Write Note

Intrinsic Value

SGMO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SGMO stock under the Base Case scenario is 2.58 USD. Compared to the current market price of 1.88 USD, Sangamo Therapeutics Inc is Undervalued by 27%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SGMO Intrinsic Value
2.58 USD
Undervaluation 27%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sangamo Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SGMO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SGMO?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Sangamo Therapeutics Inc

Provide an overview of the primary business activities
of Sangamo Therapeutics Inc.

What unique competitive advantages
does Sangamo Therapeutics Inc hold over its rivals?

What risks and challenges
does Sangamo Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Sangamo Therapeutics Inc recently?

Summarize the latest earnings call
of Sangamo Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sangamo Therapeutics Inc.

Provide P/S
for Sangamo Therapeutics Inc.

Provide P/E
for Sangamo Therapeutics Inc.

Provide P/OCF
for Sangamo Therapeutics Inc.

Provide P/FCFE
for Sangamo Therapeutics Inc.

Provide P/B
for Sangamo Therapeutics Inc.

Provide EV/S
for Sangamo Therapeutics Inc.

Provide EV/GP
for Sangamo Therapeutics Inc.

Provide EV/EBITDA
for Sangamo Therapeutics Inc.

Provide EV/EBIT
for Sangamo Therapeutics Inc.

Provide EV/OCF
for Sangamo Therapeutics Inc.

Provide EV/FCFF
for Sangamo Therapeutics Inc.

Provide EV/IC
for Sangamo Therapeutics Inc.

Show me price targets
for Sangamo Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Sangamo Therapeutics Inc?

How accurate were the past Revenue estimates
for Sangamo Therapeutics Inc?

What are the Net Income projections
for Sangamo Therapeutics Inc?

How accurate were the past Net Income estimates
for Sangamo Therapeutics Inc?

What are the EPS projections
for Sangamo Therapeutics Inc?

How accurate were the past EPS estimates
for Sangamo Therapeutics Inc?

What are the EBIT projections
for Sangamo Therapeutics Inc?

How accurate were the past EBIT estimates
for Sangamo Therapeutics Inc?

Compare the revenue forecasts
for Sangamo Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sangamo Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sangamo Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sangamo Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Sangamo Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Sangamo Therapeutics Inc with its peers.

Analyze the financial leverage
of Sangamo Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Sangamo Therapeutics Inc.

Provide ROE
for Sangamo Therapeutics Inc.

Provide ROA
for Sangamo Therapeutics Inc.

Provide ROIC
for Sangamo Therapeutics Inc.

Provide ROCE
for Sangamo Therapeutics Inc.

Provide Gross Margin
for Sangamo Therapeutics Inc.

Provide Operating Margin
for Sangamo Therapeutics Inc.

Provide Net Margin
for Sangamo Therapeutics Inc.

Provide FCF Margin
for Sangamo Therapeutics Inc.

Show all solvency ratios
for Sangamo Therapeutics Inc.

Provide D/E Ratio
for Sangamo Therapeutics Inc.

Provide D/A Ratio
for Sangamo Therapeutics Inc.

Provide Interest Coverage Ratio
for Sangamo Therapeutics Inc.

Provide Altman Z-Score Ratio
for Sangamo Therapeutics Inc.

Provide Quick Ratio
for Sangamo Therapeutics Inc.

Provide Current Ratio
for Sangamo Therapeutics Inc.

Provide Cash Ratio
for Sangamo Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Sangamo Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Sangamo Therapeutics Inc?

What is the current Free Cash Flow
of Sangamo Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sangamo Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Sangamo Therapeutics Inc

Current Assets 58.1m
Cash & Short-Term Investments 39.2m
Receivables 10.5m
Other Current Assets 8.4m
Non-Current Assets 53.1m
PP&E 36.9m
Other Non-Current Assets 16.2m
Current Liabilities 43.2m
Accounts Payable 19.8m
Accrued Liabilities 22.6m
Other Current Liabilities 774k
Non-Current Liabilities 29m
Other Non-Current Liabilities 29m
Efficiency

Earnings Waterfall
Sangamo Therapeutics Inc

Revenue
52.8m USD
Operating Expenses
-222.2m USD
Operating Income
-169.4m USD
Other Expenses
-14.5m USD
Net Income
-183.9m USD

Free Cash Flow Analysis
Sangamo Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SGMO Profitability Score
Profitability Due Diligence

Sangamo Therapeutics Inc's profitability score is 8/100. The higher the profitability score, the more profitable the company is.

Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
Negative Revenue Growth Forecast
8/100
Profitability
Score

Sangamo Therapeutics Inc's profitability score is 8/100. The higher the profitability score, the more profitable the company is.

SGMO Solvency Score
Solvency Due Diligence

Sangamo Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
50/100
Solvency
Score

Sangamo Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SGMO Price Targets Summary
Sangamo Therapeutics Inc

Wall Street analysts forecast SGMO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SGMO is 6.32 USD with a low forecast of 2.02 USD and a high forecast of 10.5 USD.

Lowest
Price Target
2.02 USD
7% Upside
Average
Price Target
6.32 USD
236% Upside
Highest
Price Target
10.5 USD
459% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SGMO?

Click here to dive deeper.

Dividends

Sangamo Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SGMO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SGMO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

SGMO News

Other Videos

Profile

Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

392.2m USD

Dividend Yield

0%

Description

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

Contact

CALIFORNIA
Brisbane California
7000 Marina Blvd
+15109706000.0
www.sangamo.com

IPO

2000-04-06

Employees

431

Officers

CEO, President & Director
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Senior VP, CFO & Principal Accounting Officer
Ms. Prathyusha Duraibabu CPA, M.B.A.
Senior VP & Chief Development Officer
Dr. Nathalie Dubois-Stringfellow Ph.D.
Head of Research
Ms. Amy Pooler Ph.D.
Head of Technology
Mr. Gregory Davis Ph.D.
Head of Corporate Communications & Investor Relations Officer
Ms. Aron Feingold
Show More
Senior VP, General Counsel & Corporate Secretary
Mr. Scott B. Willoughby
Head of Technical Operations
Mr. Phillip Ramsey
Head of Business Development & Alliance Management
Ms. Stephanie J. Seiler CLP
Scientist II - Discovery & Translational Research
Mr. David Ojala
Show Less

See Also

Discover More
What is the Intrinsic Value of one SGMO stock?

The intrinsic value of one SGMO stock under the Base Case scenario is 2.58 USD.

Is SGMO stock undervalued or overvalued?

Compared to the current market price of 1.88 USD, Sangamo Therapeutics Inc is Undervalued by 27%.

Back to Top